Filing Details
- Accession Number:
- 0001649094-24-000090
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-04 18:45:31
- Reporting Period:
- 2024-11-01
- Accepted Time:
- 2024-11-04 18:45:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1813798 | Jim Wassil | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-01 | 8,000 | $2.42 | 213,695 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-01 | 4,955 | $106.34 | 208,740 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-01 | 2,174 | $107.20 | 206,566 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-01 | 631 | $108.25 | 205,935 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-01 | 240 | $108.93 | 205,695 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-11-01 | 8,000 | $0.00 | 8,000 | $2.42 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 26,638 | 2029-12-16 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $105.75 to $106.74. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $106.75 to $107.60. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $107.86 to $108.505. The reporting person will provide upon request to the SEC, the issuer or security holder ofthe issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
